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Available online 11 November 2016Aim: Results from EuroCaReD study should serve as a benchmark to improve guideline adherence and treatment
quality of cardiac rehabilitation (CR) in Europe.
Methods and results: Data from 2.054 CR patients in 12 European countries were derived from 69 centres. 76%
were male. Indication for CR differed between countries being predominantly ACS in Switzerland (79%),
Portugal (62%) and Germany (61%), elective PCI in Greece (37%), Austria (36%) and Spain (32%), and CABG in
Croatia and Russia (36%). A minority of patients presented with chronic heart failure (4%). At CR start, most pa-
tients already were undermedication according to current guidelines for the treatment of CV risk factors. A wide
range of CR programme designs was found (duration 3 to 24weeks; total number of sessions 30 to 196). Patient
programme adherence after admission was high (85%). With reservations that eCRF follow-up data exchange
remained incomplete, patient CV risk proﬁles experienced only small improvements. CR success as deﬁned by
an increase of exercise capacity N25Wwas signiﬁcantly higher in young patients and thosewhowere employed.
Results differed by countries. After CR only 9% of patients were admitted to a structured post-CR programme.
Conclusions: Clinical characteristics of CR patients, indications and programmes in Europe are different. Guideline
adherence is poor. Thus, patient selection and CRprogrammedesigns should becomemore evidence-based. Rou-
tine eCRF documentation of CR results throughout European countries was not sufﬁcient in its ﬁrst application
because of incomplete data exchange. Therefore better adherence of CR centres to minimal routine clinical stan-
dards is requested.
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.1. Introduction
Cardiovascular (CV) disease is the leading cause of death. It is re-
sponsible for almost a quarter of the disease burden in Europe resulting
in substantial direct and indirect healthcare costs [1]. However, the
enormous engagement in the development and availability of high
technology diagnostic and therapeutic procedures for treatment of CV
disease in recent decades is associated with increased survival and
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CV conditions are chronic and often reﬂect long-term patterns of un-
healthy lifestyles and/or deconditioning of patients, beneﬁt is not auto-
matically achieved through high technology interventions and
pharmacological management alone. Several studies suggest that pre-
ventive measures are responsible for at least half of the improvement
[3]. Therefore patients need to be professionally supported to regain
or maintain physical capacity and to achieve changes in lifestyle, risk
factor management, better well-being and social and vocational partic-
ipation [4]. Cardiac rehabilitation (CR) is the structured and multicom-
ponent intervention to deliver these services [5].
Evidence of the beneﬁts of CR has been well established [6–8]. In its
consequence CR is categorised as a Class I recommendation in the ACRF/
AHA guidelines for themanagement of patients with ST-elevationmyo-
cardial infarction [9], and a Class IIa recommendation in the ESC Guide-
lines for patients after acute myocardial infarction [10].
Effectiveness of CR, however, strongly depends on minimal stan-
dards to be delivered and guaranteed during all day care in clinical prac-
tice. Therefore the need for a continuous and interactive quality
assurance process is crucial. An effective quality assurance, however,
only can be achieved by a regular and structured exchange of institu-
tional and clinical data including their continuous scientiﬁc evaluation.
The ﬁrst representative evaluation of CR activities in European Union
Member States was the Carinex Survey published in 2002 [11]. In
2008 the EACPR introduced the European Cardiac Rehabilitation Inven-
tory Survey (ECRIS) to investigate the status of CR in European countries
[12]. The ECRIS study provided information on the CR structure, legisla-
tion, funding mechanisms and national guidelines. However, neither
Carinex nor ECRIS was designed to deliver information about baseline
clinical variables and outcome data of patients admitted to CR. But the
success of CR service provision depends on data collection and quality
assessment provided by a common, international core database and
data standard across Europe.
Therefore the European Cardiac Rehabilitation Registry and
Database (EuroCaReD) was introduced as the next step after Carinex
and ECRIS to get information about CR across Europe from a predomi-
nantly clinical perspective. Cardiology Audit and Registration Data
Standards (CARDS) for Europe and collection of a common core
dataset across CR centres in European countries has been promoted
earlier [13]. Based on this core dataset EuroCaReD aimed to assess the
current CR practice in clinical all day care using a web-based data
collection system.
The purpose of the EuroCaReD project was to put together informa-
tion on the clinical status of CR across European countries by using an
electronic case report form (eCRF) to consider how this data match in
different countries and what parts of the CR have to be better
standardised in accordance with the current guidelines to improve
treatment results.
2. Methods
2.1. Study aims and characteristics
The aimswere to develop and test the feasibility and practicability of
aweb-based registry in European countries that routinely provides data
on CR settings, contents and interventions, clinical characteristics of pa-
tients and outcomes and thereby serves as basis for a regular European
quality assessment of CR services and results. Participation to
EuroCaReD was voluntary.
EuroCaReD was designed as a central internet database (http://
www.eurocared.org) being connected to national registries and local
databases of individual CR centres. The database itself was located in
the European Heart House, Sophia Antipolis, France, hosted by Solarys
IT Company, Götzis, Austria. All data were collected electronically
using a web-based data entry system. The datasets were based on the
CARDS model [13], and include items reﬂecting characteristics of theindividual institution, patient's characteristics and actual CR perfor-
mance standards [14].
2.2. Enrolment of study population
All European countries being members of the European Association
for Cardiovascular Prevention and Rehabilitation (EACPR) have been
invited to be part of the survey and 69 CR centres in 12 European
countries could be selected by the national study coordinators to
participate. Following the “snapshot” design of this study, for
consecutive enrolment of patients undergoing CR a predeﬁned time
window of 8 weeks has initially been arranged. Because of insufﬁcient
patient inclusion within the ﬁrst time period, a second prolonged time
period of another 24 weeks has been offered to the participating CR
centres for data collection. Except of Germany, participating only the
second period, all centres collected their data within both time frames
(October 1st, 2010 to November 30th, 2010, and October 1st, 2011 to
February 28th, 2012). Informed consent of all participating patients
was obtained according to the national regulations of the participating
country.
2.3. Electronic case report form (eCRF)
The selection of variables aimed to closelymirror CR all day care and
included the initiating clinical event (Table 1), demographic details
(age, gender, employment status), history of CV risk factors (hyperten-
sion, hyperlipidaemia, diabetes, overweight/obesity, smoking, physical
inactivity, depression) (Table 2), and CV risk factors as evaluated at
the CR start and CR end (blood pressure, LDL-cholesterol, fasting glu-
cose, body mass index, smoking status, watts achieved during exercise
testing) (Table 4). Current medication at CR start has also been evaluat-
ed (Table 3). All these items have been tested for conformity in the par-
ticipating countries. A complete overview on all eCRF items is given in
Appendix 1.
2.4. Follow-up
Follow-up was limited to the duration of the individual rehabilitation
programme, which varied considerably between 3 weeks (Hungary,
Germany) and 24 weeks (Greece). Clinical follow-up data entered into
the EuroCaReDdatabase at the end of the regular CRprogramme included
clinical events during CR, premature ending of the CR-programme, cur-
rent risk factors, exercise capacity and medication.
2.5. Testing CR success
Due to limited follow-up time and data acquisition not monitored by
an independent clinical research organisation (CRO), CR success could
not be evaluated by its effect on clinical prognosis. Moreover, as manage-
ment of CV risk factors like hypertension, hyperlipidaemia and diabetes
already is started by therapeutic attempts preceding CR these items can-
not serve as prognostic surrogate parameters. From this background and
because all participating centres were offering bicycle exercise training as
amajor programme content, CR success has retrospectively been deﬁned
as “exercise capacity” gained during the CR process. Therefore, CR was
regarded to be successful, if the “gain of exercise capacity” during CR
was N25 W from CR start. This assumption is based on the experience
in clinical practice and the need to reﬂect a heterogeneous population
with a large variety of exercise capacities at baseline.
2.6. Data management
Data were anonymously entered online into the eCRF at each individ-
ual study site and stored in the central EuroCaReD database. To maintain
patient's anonymity, only the identiﬁcation number of each study partic-
ipant was transferred to the central database. Patient's re-identiﬁcation
Table 1










































































































































































































































aPercentages of patients being evaluated.
bNumber of patients with the index diagnosis versus total numbers of patients being evaluated (compare also with the total number of patients being recruited, left column). 
cIncludes patients with ICD-system, pacemaker, stable angina.
dRomania: 23.8% patients with stable angina; yellow background = referral diagnosis represents 10–30%; grey background = above 30%.
60 W. Benzer et al. / International Journal of Cardiology 228 (2017) 58–67was possible only at the sites, where patients originally were
enrolled to enable additional information if needed. The Institut für
Herzinfarktforschung (IHF) Ludwigshafen, Germany provided overall
data management, statistical analysis and site-speciﬁc reports.
All collected data were offered to the national coordinators for
benchmarking and quality control within the country where the data
have been collected. Benchmarking of individual centres' data with
the pooled data of the other centres was possible after permission by
the EuroCaReD steering committee and the national coordinators. No
data from any individual centre were released to other centres.
2.7. Statistical analysis
Continuous variables are presented as means with standard devia-
tions medians with 25th and 75th percentiles and were compared byusing Wilcoxon test. Categorical variables and completeness of docu-
mentation (data availability) are presented as absolute numbers or per-
centages and were compared by using chi-square test. The statistical
comparisons were two-tailed, and p-values b0.05 were considered as
statistically signiﬁcant. For identifying independent predictors of
drop-out from CR a logistic regression analysis was done. All analyses
were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC,
USA).2.8. Ethical review board approval
The national coordinators of the EuroCaReD project were responsi-
ble for getting approval of the national or local ethical committees, ac-
cording to the prevailing national requirements.
Table 2






















activity (%) (DA %)b
Depression
(%) (DA %)b
Austria 544 59.0 50.7 50.7 59.6 13.1 29.0 54.7 29.0 NA
19.7 (94) (92) (92) (92) (92) (33) (92)
Belgium 232 62.5 51.4 47.7 66.8 19.2 36.9 29.0 55.6 11.6
23.3 (60) (92) (90) (92) (89) (92) (84) (75)
Croatia 93 62.0 59.1 86.0 94.6 34.8 35.5 31.2 55.9 1.1
23.7 (100) (100) (99) (99) (100) (100) (100) (75)
Croatia 153 61.0 52.1 52.1 86.1 22 44.7 47.6 46.5 7.6
24.8 (86) (94) (94) (95) (92) (93) (54) (86)
Germany 204 58.0 36.2 72.3 88.0 23.6 44.1 38.4 62.0 13.2
20.6 (99) (99) (98) (99) (100) (99) (84) (93)
Greece 139 65.0 72.8 84.1 71.9 23.7 16.5 33.8 80.3 3.6
30.2 (98) (99) (100) (100) (100) (98) (95) (99)
Hungary 120 60.0 52.5 85.7 73.9 29.7 43.7 55.9 73.9 3.4
24.2 (100) (99) (99) (99) (99) (99) (99) (98)
Portugal 157 59.0 35.5 55.8 69.0 24.3 34.0 35.9 83.8 16
19.7 (99) (99) (99) (97) (97) (99) (99) (99)
Romania 169 62.0 62.8 78.1 58.0 25.4 42.0 32.1 72.3 17.6
42.6 (81) (100) (100) (100) (100) (98) (88) (88)
Russia 151 57.0 29.3 84.1 60.7 15.9 47.3 43.3 43 9
23.8 (99) (100) (99) (100) (99) (99) (99) (95)
Spain 38 57.0 34.8 50.0 57.9 35.1 40.5 44.4 63.2 11.1
10.5 (61) (100) (100) (99) (99) (99) (100) (99)
Switzerland 54 60.5 61 63.0 51.9 16.7 29.6 52.8 42.3 7.4
22.2 (78) (100) (100) (100) (100) (99) (98) (100)
Total population 2054 61.0 48.7 64.4 69.0 16.9 36.0 32.4 53.7 9.8
23.8 (90.0) (96.4) (96.0) (96.1) (95.8) (80.1) (91.4) (67.8)
a Median.
b DA, data availability deﬁned as % of patients of the study population being evaluated for the individual item under consideration.
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3.1. Study population
Primarily 2.095 patients from 71 CR centres in 14 European countries
have been enrolled during the predeﬁned study periods. After examina-
tion for minimal requirements of data completeness two countries
were excluded. Thereby data from 2.054 patients from 69 CR centres of
12 European countries were suitable for the ﬁnal analysis. The numbers
of patients being enrolled in each country are given in Tables 1–4.Table 3
Patients prescribed medication at CR programme start.
Country N
Medication as applied in % of patients evaluated (patients
ASS TP BB ACE-
Austria 544 81 64.6 80.4 49.4
(29) (29) (29) (29)
Belgium 232 91 36.4 85 47.2
(63) (62) (63) (61)
Croatia 93 83.7 58.7 96.7 65.2
(99) (99) (99) (99)
Denmark 153 92.9 64.2 79.2 44.3
79/85 43/67 61/77 31/70
Germany 204 83.7 56.7 86.1 63.9
(99) (98) (99) (99)
Greece 139 80 31.4 93.4 86
96/120 38/121 113/121 104/1
Hungary 120 89.2 62.5 97.5 75.8
107/120 75/120 117/120 91/12
Portugal 157 95 87.2 86.3 72.9
148/155 136/156 132/153 113/1
Romania 169 84.7 46 88.3 73
(116/137) (63/137) (121/137) (100
Russia 151 94.5 51 91.7 77.2
(137/145) (74/145) (133/145) (112
Spain 38 94.4 44.4 77.8 55.6
(17/18) (8/18) (14/18) (10/1
Switzerland 54 81.4 81.4 88.4 65.1
(35/43) (35/43) (38/43) (28/43.2. Clinical events initiating CR
Regarding the entire study population, patients with coronary ar-
tery disease (CAD) represented the vast majority of CR patients
(83%). The most common initiating events for CR referral were
acute coronary syndrome (ACS) (40%) and elective PCI (22%),
followed by patients after CABG (19%) (Table 1). The number of pa-
tients admitted for CR because of chronic heart failure (CHF) was
low (4%). Themost relevant comorbidities weremusculoskeletal dis-
orders (18%) and COPD (11%).treated/patients evaluated)
I ARB Statin Oral diabetes control Insulin
NA 81.6 9.5 2.5
(29) (29) (29)
5.9 81.4 16.1 4.2
(59) (63) (62) (62)
19.8 91.3 23.3 3.3
(98) (99) (97) (98)
17.2 91.9 19.7 9.4
11/64 79/86 13/66 6/64
17.8 81.2 15.5 9.5
(99) (99) (98) (99)
14.2 93.4 16.5 2.5
21 17/120 113/121 20/121 3/121
16.8 87.5 21.8 7.6
0 20/119 105/120 26/119 9/119
12.9 94.2 21.3 8.4
55 20/155 146/155 33/155 13/155
14 85.3 17.6 2.2
/137) (19/136) (116/136) (24/136) (3/137)
5.5 93.8 9.7 0.0
/145) (8/145) (136/145) (14/145) (0/145)
16.7 100 22.2 0.0
8) (3/18) (18/18) (4/18) (0.18)
25.6 88.4 4.7 9.5
3) (11/43) (38/43) (2/43) (4/42)
62 W. Benzer et al. / International Journal of Cardiology 228 (2017) 58–67The distribution of initiating events exhibited a considerable hetero-
geneity between the participating countries.Whereas ACS dominated in
Switzerland (79%), Portugal (62%) and Germany (61%), elective PCI for
stable CAD was prominent in Greece (37%), Austria (36%) and Spain
(32%). Only in Switzerland CR referral of patients with NSTEMI (33%)
was comparable to the group of patients with STEMI, whereas in some
countries NSTEMI patients were not represented at all within this sur-
vey (e.g. Greece). Patients after CABG represented the largest group in
Croatia and Russia (36% each).3.3. Demographic characteristics and history of CV risk factors
The mean age of the total population was 58 ± 16 years with low
variations between the countries. 76% of the study population were
male. Female patients represented the minority in all countries and
ranged from 10% in Spain to 43% in Romania. At CR start almost half of
the patients were retired (49%) with a maximum in Greece (73%) and
a minimum in Russia (29%).
Most patients had a typical CV risk proﬁle with a history of hyper-
lipidaemia (69%), hypertension (64%), lack of regular physical activ-
ity (54%) and smoking (40%). However, the distribution of the
individual risk factors in patients' history considerably varied be-
tween countries. Percentages were displayed in Table 2. The distri-
bution was in hypertension from 48% (Belgium) to 84% (Russia); in
hyperlipidaemia from 52% (Switzerland) to 95% (Croatia); in
diabetes mellitus from 13% (Austria) to 35% (Spain); in over-
weight/obesity form 16% (Greece) to 47% (Russia); in smoking
from 29% (Belgium) to 53% Switzerland; in low/no physical activity
from 29% (Austria) to 84% (Portugal); and in depression from 1%
(Croatia) to 18% (Romania).Table. 4



























Austria 544 128.8 [243] 104.2 [275] 140.9 [42]
−3.8 [165] −17.6 [197] −4.9 [34]
Belgium 232 138.3 [68] 104.4 [71] 126.9 [15]
−2.5 [39] −34.2 [29] −29.3 [3]
Croatia 93 132.0 [80] 87.6 [87] 145.5 [31]
−10.9 [78] −7.0 [29] −17.2 [29]
Denmark 153 138.2 [67] 100.0 [110] 130.6 [23]
+1.4 [37] −24.2 [71] −13.6 [9]
Germany 204 129.7 [145] 107.7 [165] 135.9 [43]
−5.9 [141] −17.9 [136] −14.1 [39]
Greece 139 117.9 [109] 111.4 [94] 117.8 [28]
+0.03 [104] −1.5 [89] −1.1 [25]
Hungary 120 133.3 [102] 110.0 [54] 139.9 [27]
−9.3 [102] −16.0 [24] −5.5 [25]
Portugal 157 133.2 [86] 112.9 [94] 154.4 [33]
−7.9 [73] −22.6 [75] −21.0 [28]
Romania 169 138.5 [103] 141.9 [70] 139.3 [34]
−8.9 [74] −38.9 [48] −12.7 [23]
Russia 151 129.4 [127] 123.2 [69] 117.0 [24]
−8.6 [120] −13.4 [13] −18.8 [19]
Spain 38 128.9 [9] 91.2 [13] 109.1 [7]
−12.5 [8] −15.5 [12] −3.4 [5]
Switzer land 54 125.7 [34] 92.9 [13] 142.6 [2]
+6.8 [26] NAc NAc
All
countries
2054 130.7 [1173] 108.0 [1108] 135.7 [309]
−5.7 [967] −18.3 [723] −10.8 [239]
a Mean values; to increase clarity of presentation standard deviations are not presented.
b Smoking status at the end of CR has not been sufﬁciently reported, and therefore cannot b
c NA, data not available.3.4. Baseline hemodynamic parameters and medication prescription in pa-
tients referred to CR
The large majority of patients were in sinus rhythm. At CR start
mean heart rate at rest was 69 bpm and mean left ventricular ejection
fraction (LVEF) 54%. All patientswere on guideline-adjustedmedication
before starting the CR programme (Table 3).
3.5. Changes of individual risk factors during CR programme
Table 4 presents CV risk factor data at CR start and end of those pa-
tients with the individual risk factors reported in history (Table 2).
With respect to blood pressure, LDL-cholesterol and baseline glucose,
patients were already on medication at CR start but the values still
could be optimized during CR (values at CR start and change as mea-
sured at CR end: systolic blood pressure 131 = minus 5 mm Hg; LDL-
cholesterol: 108 mg/dl = −18 mg/dl; and fasting glucose
136 mg/dl = −11 mg/dl. Notably, baseline measurements of these
risk factors were incomplete, and controls were performed even less.
Mean BMI of patients with overweight or obesity in history was
32 kg/m2, and a relevant reduction could not be achieved during CR.
From the group of patients with history of smoking a relevant part al-
ready stopped before CR start, however, this part showed a large varia-
tion between the countries (Table 4). Unfortunately the further course
of smoking behaviour has not been reported by the CR centres. There-
fore the effect of CR on smoking behaviour could not be assessed.
3.6. Exercise capacity and CR success
Exercise capacity given in “watts” could be documented only in 535

































31.3 [144] 54.7 [181] 143 [40] 96 [4]
−0.6 [101] 50.0 [178] +28 [38] +19 [2]
30.9 29.0 [214] 112 [111] 100 [53]
−0.2 [0.2] 19.9 [146] +22 [66] +17 [29]
33.9 [32] 31.2 [93] 106 [62] 94 [31]
−0.5 [24] 31.2 [93] +13 [15] +18 [10]
30.9 [54] 47.6 [143] 114 [1] NAc
+0.1 [31] 22.2 [135] NAc
32.5 [88] 38.4 [203] 98 [188] 95 [96]
−0.7 [83] 17.2 [204] +21 [148] +17 [75]
33.8 [23] 33.8 [136] 106 [11] 65 [3]
−0.3 [18] 13.0 [138] +1 [1] +1 [1]
32.6 [50] 55.9 [118] 109 [8] 109 [8]
−0.5 [49] 10.0 [120] NAc NAc
31.3 [52] 35.9 [156] NAc NAc
−1.2 [47] 23.4 [154]
33.5 [60] 32.1 [165] 74 [62] 69 [40]
−0.7 [45] 21.9 [137] +41 [29] +44 [17]
31.4 [71] 43.3 [150] NAc NAc
+0.2 [67] 39.3 [150]
27.7 [8] 44.4 [36] NAc NAc
−2.1 [7] 20.8 [24] NAc
30.6 [30.6] 52.8 [53] 113 [52] 102 [21]
0.0 [9] 13.0 [54] +30 [42] +22 [16]
31.8 [652] 40.0 [1648] 104 [535] 92 [257]
−0.5 [515] 24.7 [1533] +24 [339] +20 [150]
e presented.
Fig. 1. The diagram shows demographic, social and clinical factors potentially inﬂuencing CR success as deﬁned by an increase of exercise capacity of N25W. The percentages refer to the
size of the individual subgroup within the success or non-success group in each category or cardiovascular risk factor. The p-values refer to the differences between the success and non-
success group; *) p b 0.05, **) p b 0.01, ***) p b 0.001.
63W. Benzer et al. / International Journal of Cardiology 228 (2017) 58–67the end of CR too (339; 16% of total). Therefore repeat bicycle exercise
test results at the end of the CR programme were available only in this
small subgroup of the study population. Within this subgroup exercise
capacity changed from 104 ± 44 W at CR start to 128 ± 50 W at CR
end; p b 0.0001 (Table 4). Considering only the subgroup with patients'
history of “low/no physical activity at CR start” the increase was similar
from 92 ± 38 W at CR start to 112 ± 41 W at CR end; p b 0.0001
(Table 4).
For further differentiation “CR success” has provisionally been deﬁned
as an increase of exercise capacity of N25W after CR. On the basis of this
deﬁnition 58% (n=198) of the subgroup of patientswith repeat exercise
tests during CR successfully completed their programme. The success rate
varied according with the patients' baseline characteristics as outlined in
Fig. 1. In the subgroup of patients aged b50 years, or being employed the
number of patients with CR success signiﬁcantly exceeded the number of
unsuccessful patients. In contrast, in the subgroups of patients being re-
tired or patients after NSTEMI the majority of patients remained unsuc-
cessful in increasing their exercise capacity.Table 5
CR setting, duration and content.
Country Design Exercise (sessions per week) Couns
Austria Outpatient 3 2
Belgium Outpatient 3 1
Croatia Inpatient 4 4
Denmark Outpatient 3 2
Germany In- and outpatient 12 8
Greece Outpatient 3 1
Hungary Inpatient 5 5
Portugal Outpatient 3 2
Romania Inpatient 4 4
Russia Inpatient 4 2
Spain Outpatient 3 1
Switzerland Outpatient 3 2
Mean 4.2 2.8
a Retrospective assessment.3.7. CR programme characteristics
CR setting, content and duration varies across countries (Table 5).
Mean programme duration was 8 weeks, shortest in Hungary and lon-
gest in Greece (24 weeks). During the programmes, an average of 4.2
exercise sessions and 2.8 counselling sessions were offered weekly.
The mean total number of sessions offered during CR was 43.5, highest
in Greece (n = 96) and lowest in Austria, Denmark, Hungary, and
Portugal (n = 30).3.8. CR programme completion, recurrent CV events and drop-out rate
Of the 2.054 patients admitted for CR, 85% completed the pro-
gramme. The most common reasons for patient drop-out were patient
non-compliance (31%), and recurrent CV events within the CR pro-
gramme timeframe (8%). But in 60% of the drop-outs the reason has














64 W. Benzer et al. / International Journal of Cardiology 228 (2017) 58–673.9. Post-CR disease management
After CR completion, patients returned to routine care by cardiolo-
gists (61%) and/or to a general practitioner or both (23%). But only 9%
were admitted to a structured post-CR programme such as “heart
group” or equivalent activities.
3.10. Subgroup analysis for gender
There was no gender difference in age of CR participants. Fewer
women than men were married (70% vs. 83%; p b 0.0001) but more of
them were widowed (15% vs. 4%; p b 0.0001). A higher percentage of
women were retired (54% vs. 45%; p b 0.001). Signiﬁcant differences
could be observed in the presence of CV risk factors. Fewer women
than men reported a history of smoking (28% vs. 44%; p b 0.0001),
whereas more women were hypertensive (71% vs. 62%; p b 0.001) or
obese (41% vs. 34%; p b 0.01). Fewer women than men were regularly
physically active (35% vs. 49%; p b 0.001). More women than men had
a history of depression (17% vs. 7%; p b 0.0001).
During the CR programme, similar number of recurrent events oc-
curred inwomen and inmen (9.6% vs. 9.0%). Dropout rates did not differ
betweenwomen andmen (14%vs. 15%). OnCR programme completion,
women experienced similar improvement of physical exercise capacity
in watts (22 ± 18 vs. 25 ± 23).
3.11. Documentation and data availability
Availability of datawas limited and varied between the participating
countries (Tables 2–4). This is exempliﬁed by the data availability of the
item in patients' history “low/no physical activity” (Table 2) ranging
from 54% (Denmark) to 100% (Croatia, Spain), and the item “exercise
capacity — change during CR”, ranging from 0% (Denmark, Hungary,
Portugal, Russia, Spain) to 78% (Switzerland) (Table 4). Moreover,
change of smoking behaviour during CR has not routinely been
assessed. Therefore no reliable data could be gained from this item too.
4. Discussion
To the best of our knowledge, EuroCaReD presents the ﬁrst eCRF
based international registry of baseline patient characteristics, indica-
tions, treatment and outcomes in “all-comers” admitted to a CR pro-
gramme in Europe. Beyond assessment, clinical registry programmes
provide an important tool to monitor quality of healthcare services
and thereby improve clinical outcome. Through registry evaluation,
more effective and efﬁcient systems of CR delivery can be detected.
This supports a wider coverage of those patients who can beneﬁt in
the future [11]. As a continuation of the previous Carinex and ECRIS pro-
ject the major tasks of EuroCaReD were:
1. to test the feasibility of a web-based eCRF for collecting clinical
baseline and outcome parameters in patients surpassing a CR pro-
gramme and
2. to deﬁne measures that can serve as a benchmark to improve
guideline adherence and treatment quality of CR in Europe.
4.1. Heterogeneity of CV risk factor proﬁles across European countries
As EuroCaReD baseline data show, the four most common CV risk
factors in patients referred to CR across Europe are hyperlipidaemia, hy-
pertension, low/no physical activity and cigarette smoking. This obser-
vation matches with the recently published EuroAspire IV study [15].
As in EuroAspire IV, in EuroCaReD the distribution of the individual
risk factors in patients' history considerably varied between the coun-
tries. But EuroCaReD ﬁndings could not conﬁrm observations of
EuroAspire IV that large proportions of CAD patients do not achieve
therapeutic targets for CV disease prevention. In the EuroCaReD popula-
tion most patients reported adequate prescription of medication evenbefore admission to CR. The different study population could explain
this. Whereas in EuroAspire IV patients without documented CAD
were asked about their medication, in EuroCaReD all patients presented
after a CAD event. Obviously, adequate prescription of cardio-protective
medication following evidence-based guidelines is consideredmore im-
portant in secondary than in primary prevention of CAD.
4.2. Unity and diversity of CR patient baseline clinical parameters in differ-
ent European countries
As in most other reports EuroCaReD overall results show that pa-
tients with CAD represented the majority of CR candidates. In accor-
dance with the guidelines for the clinical management of patients
with CAD [14], the most common initiating events in patients referred
for CR in European countries are ACS and elective PCI, followed by pa-
tients after CABG. But the number of patients admitted for CR because
of CHF is surprisingly low and does not meet the requirements given
by the current guidelines. Looking to the numbers in various European
countries, despite of the current guidelines issued by the European Soci-
ety of Cardiology [14] the distribution of clinical events initiating CR ex-
hibited a considerable heterogeneity whereas ACS including NSTEMI
and STEMI as an important indication for CRwas adequately recognised
only in Switzerland, Portugal and Germany. In some countries NSTEMI
patients were not represented at all (e.g. Greece). Obviously because
revascularisation strategies of CAD in Eastern European countries tend
more to surgery, in Croatia and Russia patients after CABG represented
the largest group of CR patients. Thus EuroCaReD results show lack of
guideline adherence in terms of the most important indication for CR
in several European countries.
4.3. Heterogeneity of CR programme delivery across European countries
As shown in ECRIS before, a surprisingly wide spread in CR pro-
gramme content and length has to be noted by EuroCaReD across
European countries.Whereas in Eastern Europe and Central Europe, ex-
cept Austria and Germany where outpatient CR is becomingmore com-
mon, a short in-patient CR setting has emerged, most other European
countries contrast with the tradition of the out-patient setting, which
in general is offered over a longer period. The best scientiﬁc evidence
of improvement in morbidity and mortality in the literature is found
for programmeswithmore sessions and longer duration [16]. Therefore
prompted by ECRIS and now by EuroCaReD, across Europe consensus
should be found in future on programme content and duration, as
well as on patient characteristics for each CR setting. This should be
based on scientiﬁc evidence or speciﬁc medical needs, independent of
the development of traditional forms of CR, inﬂuenced by local
particularities.
4.4. CR programme patient adherence throughout Europe
In the EuroCaReD study sites, only about 15% of patients did not
complete the CR programme, mostly because of patient related reasons
rather than medical complications. In a questionnaire study from
Denmark, authors found 21% drop-out, with deterioration of physical
conditions, lack of time, long distance from residence to hospital, trans-
port problems and lack of understanding of the beneﬁts of CR as the
main determinants for drop-out [17]. In another more recently pub-
lished report from Canada, in accordance to EuroCaReD results the rea-
son for premature termination was most often due to patient dropout
(87%) [18]. These observations provide targets to address compliance
problems in CR programmes. In particular, patients who have to inter-
rupt their programme because of medical interventions should be
readmitted to CR as soon as possible. As the drop-out risk in EuroCaReD
institutions was also high in patients with comorbidities, these sub-
groups should receive special attention. The high percentage of patients
with unspeciﬁed reasons of CR programme interruption in EuroCaReD
65W. Benzer et al. / International Journal of Cardiology 228 (2017) 58–67needs further qualitative investigation to develop descriptive categories
for future study.
4.5. CR programme success in European countries
The assumption that a CR programmewas successful for the patient
has to be weighted in consideration to the targets that the institution
has deﬁned with the patient based on his individual needs, CV risk pro-
ﬁle and the current guidelines. Because all participation institutions of-
fered exercise based CR, in EuroCaReD CR success was provisionally
deﬁned as an increase of exercise capacity of a minimum of 25 W at
the end of programme. By this deﬁnition at least more than half of the
subgroup of patients with repeat exercise tests during CR successfully
completed their programme. Not surprisingly, patients aged
b50 years, patients being employed and, because of low exercise capac-
ity before programme start, patients after CABG or after STEMI had the
highest success rate. Between countries the improvement of exercise
capacity varied considerably, obviously because of wide spread in CR
programme content and length. But mean improvement of exercise ca-
pacity during CR throughout European countries was comparable with
results of other reports [18,19].
4.6. Changes of individual risk factors during CR programme
Only small improvement in CV risk factors, most likely because of
the high pre-medication rate in lipid lowering, blood pressure and
diabetes treatment could be documented. In our experience, many
patients entered CR very soon after the initiating event and in this
situation the medication was still optimally prescribed. Thus pa-
tients entering CR presented lipid levels ranging in the treatment
targets and further lowering would not be expected by CR pro-
gramme activities. So a major task of CR is to get patients to maintain
medication and other preventive interventions and treatments by
education and motivation. Consistently the EuroAspire III study re-
sults show that control of smoking and the use of cardio-protective
medication works better in patients who attend a CR programme
[20]. EuroCaReD results conﬁrmed these observations. The decrease
in number of cigarettes smoked during the CR time period can be
rated as a positive effect because there is a linear relationship be-
tween number of cigarettes smoked and residual risk [21]. Because
of the short observation period EuroCaReD results could not provide
a ﬁnal evaluation on adherence of CR programme effects.
4.7. Continuation of secondary prevention after ﬁnishing CR programme
To reach long lasting effects of the CR programme on CV risk factors
and physical exercise performance effects, long-term care models are
crucial. Post CR disease management programmes have been
established in many European countries. In three-quarters of the coun-
tries that participated in the ECRIS registry, cardiologists are responsible
for post-CR patient care often in collaboration with a specialist in inter-
nal medicine and/or physiotherapist [12]. The EuroCaReD results reﬂect
this observation. Because of their structured offering it would be advan-
tageous if more than the current level of less than 10% of post CR pa-
tients could be admitted to heart groups supervised by an exercise
therapist depending from the country where CR patients are living.
4.8. Comparison of EuroCaReDpatient characteristicswith other CR surveys
In accordance with other registries in- and outside Europe,
EuroCaReD results show that much more men than women are admit-
ted to CR programmes. EuroCaReD ﬁndings, demonstrating equal CR
beneﬁt for women andmen, highlight the need of measures to increase
the participation rate of women in CR programmes. In accordance to
other parts of the world most patients are admitted for CR because of
CAD. But at least in Western Europe more patients after ACS areadmitted (40% of all admitted) as e.g. in Canada (20% of all admitted)
[18]. Therefore EuroCaReD patient characteristics and indications for
CR correspondmore to recently published reports that show the preva-
lence of ACS as the CR initiating event [19,22]. In comparison to the ex-
perience of the national investigators of the ECRIS survey, EuroCaReD
reported most patients after ACS admitted to CR, but similarly few pa-
tients with CHF [12]. Thus EuroCaReD results conﬁrm ﬁndings reported
in other surveys that CHF patients are underrepresented in exercise-
based CR programmes [23]. Although in CHF patients, exercise-based
CR does not signiﬁcantly decrease the risk of all-cause and CVmortality
[24], but it reduces hospital readmissions and confers important im-
provements in health-related quality of life [25,26]. Therefore much
more CHF patients should be admitted in CR programmes than current-
ly practiced.4.9. Strengths and limitations of the study
In terms of strengths, the EuroCaReD prospective study documents
clinical characteristics, treatments and programme outcomes of pa-
tients admitted to CR in different European countries representing
usual care across Europe. The registry covers a large population, provid-
ing an overview over similarities but also heterogeneity of CR
programmes. Because of the standardised data collection following the
CARDS system, the EuroCaReD eCRF can be used as a benchmark
throughout European countries. This should enable the CR community
to establish more uniform programmes with uniﬁed objectives to
achieve better treatment results.
This study has several limitations. Availability of data was limited
and varied between the participating countries. Therefore caution is
warrantedwhen interpreting the data, primarily due to generalizability.
In terms of generalizability it has also to be noted that our ﬁndings are
limited to only 12 European countries where CR institutions were able
to contribute data. There is also a possibility that CR centres participat-
ing in the survey are most motivated regarding quality assessment
and more adherent to evidence-based guidelines. This might result in
a selection bias.
Lessons from the limitations of this study caution against
lengthy data collection aspirations although the source of collec-
tion is a routine clinical programme. EuroCaReD eCRF data collec-
tion shows that implementing of electronic reporting alone is not
enough relief to achieve sufﬁcient data. To collect high quality
data, a robust audit system seems to be crucial. Extra scrutiny
should be applied to units where the data collection processes ap-
pear to be inadequate.5. Conclusions
To test guideline adherence and treatment quality of CR in Europe
this survey provides data of “all-comers” admitted to a CR programme
in 12 European countries. Overall patient baseline characteristics at CR
programme admission meet the evidence-based guidelines. This also
applies to the cardio-protective medication prescription before admis-
sion to CR. Nevertheless there are still differences in guideline adher-
ence between countries. Underutilization of CR could be discovered in
Europe especially in women and patients with CHF, and in some coun-
tries in ACS patients too. This clearly demonstrates a lack of evidence-
based guideline adherence. Therefore subgroups where the beneﬁt of
CR is underestimated should be specially targeted even because the ad-
herence of patients to CR programmes after admission is high. Deﬁcits
could also be found in the uniformity of CR programmes throughout
Europe. The heterogeneity of programme design and duration requires
better measures that lead to better treatment results, particularly be-
cause this ﬁrst application of eCRF documentation of CR results in
European countries was not sufﬁcient enough.
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